Anesth Analg 2001;93:1480-1482
© 2001 International Anesthesia Research Society
CARDIOVASCULAR ANESTHESIA
Hemostatic Analysis of a Patient with Hereditary Angioedema Undergoing Coronary Artery Bypass Grafting
James D. Chaney, MD*,
Thomas M. Adair, MD*,
William A. Lell, MD*,
David C. McGiffin, MD , and
Vance G. Nielsen, MD*
Departments of *Anesthesiology and Surgery, The University of Alabama at Birmingham, Birmingham, Alabama
Address correspondence and reprint requests to Vance G. Nielsen, MD, Department of Anesthesiology, The University of Alabama at Birmingham, 619 South 19th Street, Birmingham, Alabama 35249. Address e-mail to vance.nielsen{at}ccc.uab.edu
 |
Abstract
|
|---|
IMPLICATIONS: Hereditary angioedema is a disease associated with acute complement-mediated inflammation and swelling of the airway and other vital organs. This case describes the impact of hereditary angioedema and cardiopulmonary bypass on hemostasis as assessed by thrombelastography.
|
Introduction
|
|---|
Hereditary angioedema (HAE), also known as hereditary angioneurotic edema, is an autosomal dominant disease with an incidence of 1 in 10,000 and is associated with episodes of acute swelling of the extremities, face, gastrointestinal tract, and airway (1). Although HAE is associated with a deficiency of functional C1 esterase inhibitor (C1INH) (2), the diagnosis of HAE is primarily based on clinical symptoms and family history. Patients with HAE may have normal or even supranormal C1INH activity but may still require chronic androgen or acute fresh-frozen plasma (FFP) administration to further increase C1INH activity to control their disease (3–6). C1INH not only regulates the initiation of the classical complement pathway but also regulates the activities of Factor XI and Factor XII, potentially enhancing the contact pathway of coagulation and fibrinolysis (3,7). Therefore, in addition to increased complement-mediated systemic inflammation associated with cardiopulmonary bypass (CPB), patients with HAE could potentially have enhanced hemostasis or exaggerated fibrinolysis during CPB.
Previous reports have documented serial complement analysis during CPB in an attempt to better understand the impact this disease has on the inflammatory state associated with CPB (3,8,9). We present a case describing the impact of HAE on coagulation as assessed by serial thrombelastography (TEG®; Haemoscope, Skokie, IL) before, during and after CPB.
|
Case Report
|
|---|
The patient was a 58-year-old, 70-kg female with a 30-year history of HAE scheduled for coronary artery bypass grafting (CABG) surgery. She had unstable angina, symptoms of pulmonary venous hypertension, three-vessel coronary artery disease and an ejection fraction of <0.3. She had a family history of HAE (grandfather, uncle, mother, sister, and daughter) and had had multiple HAE attacks involving her extremities, face, colon, and oropharynx. She denied requiring emergent intubations or tracheotomy. Although noncompliant with her androgen therapy, she had been maintained on a prolonged course of methylprednisolone as well as antidepressants for mood control. Before the cardiothoracic anesthesia service was aware of the patient, she received a 6-day preoperative course of stanozolol 4 mg per os three times daily. The patient was administered 2 U of FFP on the morning of surgery to increase C1INH activity as recommended by the consultant hematologist. Before FFP administration, the patient had a prothrombin time of 13.1 sec (control value 12.4–14.4 sec), an activated partial thromboplastin time (aPTT) of 25 sec (control value of 25–34 sec) and a platelet count of 340,000 mm3. Preoperative TEG® analysis was performed before FFP administration via venipuncture, with the first 5 mL of blood discarded and a subsequent 2.7 mL anticoagulated with 0.129 M sodium citrate. Citrated blood was used, as it was not feasible to transport this sample to the TEG® in under 4 min. Consequently, all subsequent blood samples (obtained from a pulmonary artery catheter) were also citrated for consistency and placed into a computer-controlled TEG® within 40–60 min. The samples consisted of 330 µL of citrated blood to which was added 10 µL of normal saline or the platelet inhibitor cytochalasin D (10 µM final concentration), as has been previously described (10,11). TEG® analysis methodology is described in previous publications (10,11). Lastly, blood was recalcified with 20 µL of 2 M CaCl2, with TEG® analysis performed for 60 min. All TEG® and other hemostatic data are depicted in Table 1.
Anesthesia was induced with propofol and maintained with a balanced isoflurane/propofol/fentanyl technique. CABG was performed with a CPB time of 66 min at 34° and an aortic cross-clamp time of 34 min. A total of 38,000 U of heparin was administered during CPB. The patient was easily weaned from CPB, and 30 min after administration of 450 mg of protamine, 2 U of FFP, and 10 U of platelets were administered for microvascular bleeding with subsequent satisfactory hemostasis obtained. Compared with previously published control values for citrated TEG® (r = 21 min, range 18–24 min) (12), the patient’s R values were 5–10 times smaller than previously reported with citrated blood during the perioperative period (Table 1). The patient’s  values were nearly double that previously reported ( = 34°, range 28–48°) (9) and maximum amplitude (MA) values were significantly greater than formerly noted (MA = 49.5 mm, range 45–60 mm) (12) (Table 1). With regard to clot strength related to coagulation proteins (GSC), the patient’s values always exceeded a value of 10% of total clot strength previously reported (10). Total postoperative chest tube drainage was 1384 mL. There were no perioperative episodes of angioedema. The patient was discharged on postoperative day 6.
|
Discussion
|
|---|
The effects of CPB on patients with HAE have been anecdotally reported (7–9), with one report (7) of fatal coagulopathy observed after CPB, whereas other cases without clinically significant coagulopathy have been noted (8,9). Patients with HAE have increased Factors XI and XII activity, and an increase in the speed of clot initiation and formation was anticipated. This was evidenced by a small R time, steep value, shortened activated clotting time (ACT), and low-normal aPTT. Further, CPB-mediated hemodilution, which has been noted to decrease and MA (13), likely decreased this hypercoagulable state, which then reappeared after CPB with its concordant redistribution of intravascular fluid. An unanticipated finding was an increase in GSC, which is primarily mediated by fibrinogen (14). Such a finding is not unprecedented, as term parturients with increased fibrinogen concentration have been noted to have protein-mediated clot strength (15), nearly double the usual 10% of total clot strength based on changes in G (10). Of interest, stanozolol administration has been associated with a significant decrease in fibrinogen (16). Therefore, we speculate that HAE may be associated with increases in circulating fibrinogen and that the fluctuations in GSC observed in the present case were secondary to CPB-associated hemodilution.
Given the hypercoagulable state observed, one might anticipate that these patients may be at risk for thrombotic disease. This is in fact not the case (3), and it has been speculated that endogenous serine protease inhibitors such as antithrombin III are capable, in concert with endogenous endothelial anticoagulant defenses, of preventing thrombosis in the presence of increased Factor XI and XII activity (3).
In summary, we present the hemostatic course of a patient with HAE requiring CPB for CABG who received a typical prophylactic regimen. Throughout the perioperative period the patient was hypercoagulable (based on TEG®-derived data), primarily mediated by an increase in coagulation protein function. Of interest, no important clinical coagulopathy was noted, nor was there any significant thrombotic morbidity. Future study is warranted to obtain a better understanding of the balance of hemostasis and endogenous anticoagulants in patients with HAE.
|
Acknowledgments
|
|---|
Supported in part by the Benjamin Carraway Endowed Chair of Anesthesiology and the Department of Anesthesiology.
|
References
|
|---|
-
Poppers PJ. Anaesthethic implications of hereditary angioneurotic oedema. Can J Anaesth 1987; 34: 76–8.[Medline]
-
Austen K. Diseases of immediate type hypersensitivity. In: Fauci A, Braunwald E, eds. Harrison’s principles of internal medicine. 14th ed. New York: McGraw-Hill, 1998: 1865–6.
-
Witzke G, Bork K, Benes P, Bockers M. Hereditary angioneurotic oedema and blood-coagulation: interaction between C1-esterase-inhibitor and the activation factors of the proteolytic enzyme systems. Klinische Wochenschrift 1983; 61: 1131–5.[Medline]
-
Sheffer AL, Fearon DT, Austen KF. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. J Allergy Clin Immunol 1981; 68: 181–7.[Web of Science][Medline]
-
Sheffer AL, Fearon DT, Austen KF. Hereditary angioedema: a decade of management with stanozolol. J Allergy Clin Immunol 1987; 80: 855–60.[Web of Science][Medline]
-
Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997; 99: 194–6.[Web of Science][Medline]
-
Bonser RS, Dave J, Morgan J, et al. Complement activation during bypass in acquired C1 esterase inhibitor deficiency. Ann Thorac Surg 1991; 52: 541–3.[Abstract]
-
Castelli R, Cicardi M. Cardiopulmonary by-pass in a patient with acquired C1 inhibitor deficiency. Int J Artif Organs 1997; 20: 175–7.[Medline]
-
Haering JM, Comunale ME. Cardiopulmonary bypass in hereditary angioedema. Anesthesiology 1993; 79: 1429–33.[Medline]
-
Khurana S, Mattson JC, Westley S, et al. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography. J Lab Clin Med 1997; 130: 401–11.[Web of Science][Medline]
-
Nielsen VG, Geary BT, Baird MS. Evaluation of the contribution of platelets to clot strength in rabbits: role of tissue factor and cytochalasin D. Anesth Analg 2000; 91: 35–9.[Abstract/Free Full Text]
-
Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in thromboelastography. Anesth Analg 2000; 90: 1086–8.[Free Full Text]
-
Tuman KJ, McCarthy RJ, Djuric M, et al. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth 1994; 8: 144–9.[Medline]
-
Kettner SC, Panzer OP, Kozek SA, et al. Use of abciximab-modified thrombelastography in patients undergoing surgery. Anesth Analg 1999; 89: 580–4.[Abstract/Free Full Text]
-
Gottumukkala VNR, Sharma SK, Phillip J. Assessing platelet and fibrinogen contribution to clot strength using modified thrombelastography in pregnant women. Anesth Analg 1999; 89: 1453–5.[Abstract/Free Full Text]
-
Berridge DC, Frier M, Westby JC, et al. Double-blind randomized trial of perioperative fibrinolytic enhancement for femoropopliteal bypass. Br J Surg 1991; 78: 101–4.[Medline]
Accepted for publication August 15, 2001.
This article has been cited by other articles:
|
|
|
|
 
D. R. Kieta, A. T. McCammon, W. L. Holman, and V. G. Nielsen
Hemostatic Analysis of a Patient Undergoing Off-Pump Coronary Artery Bypass Surgery with Argatroban Anticoagulation
Anesth. Analg.,
April 1, 2003;
96(4):
956 - 958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
Top
Abstract
Introduction
